NASD · Healthcare · Medical Devices · USA
Integra Lifesciences Holdings Corp is a small cap company (market value between $300 million and $2 billion) in the Medical Devices industry.
Integra LifeSciences is a medical technology company manufacturing and selling devices across two segments: Codman Specialty Surgical, providing technologies for neurosurgery, neurocritical care, and ENT procedures; and Tissue Technologies, offering regenerative products for wound reconstruction and care. The company serves hospitals, surgery centers, and healthcare providers globally through direct sales representatives and distributors.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Integra Lifesciences Holdings Corp stock.
Overvalued: intrinsic value $9.86 per share, market price $13.33, margin of safety -35.2% (as of 2026-10-20).
Its through-the-cycle earnings (8.0% median margin), capitalised at 8.7% with no growth, values the shares at $9.86; the price of $13.33 is 35% above that value.
Leak Score: 15/100 on 10 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
All 142 Medical Devices stocks
23 more in this industry show a wider margin of safety.
IART is overvalued (as of the 2026-10-20 close). Its through-the-cycle earnings (8.0% median margin), capitalised at 8.7% with no growth, values the shares at $9.86; the price of $13.33 is 35% above that value.
$9.86 per share (as of the 2026-10-20 close), against a market price of $13.33. That is a margin of safety of -35.2%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
15 out of 100, which we rate "On Watch", on 10 of 12 value investing signals.